#ASCO21: Novartis flashes 'groundbreaking data' for $2B radioligand drug
Here’s the “groundbreaking” data from the prostate cancer drug Novartis spent $2 billion to acquire: The molecule hit every endpoint in the Phase III trial, including extending patient lives by 4 months compared to standard of care.
“It’s strikingly positive,” Oliver Sartor, a prostate cancer expert at Tulane who led the study, told Endpoints News. “During the course of the trial, you never really know how things are shaking out, and I was very, very pleasantly surprised.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters